Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Biohaven Ltd. (NYSE:BHVN) have received an average recommendation of “Moderate Buy” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $25.5714.

BHVN has been the topic of a number of analyst reports. Sanford C. Bernstein reissued a “market perform” rating and issued a $9.00 price target (down previously from $34.00) on shares of Biohaven in a research note on Thursday, November 6th. Morgan Stanley cut their target price on Biohaven from $26.00 to $21.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 6th. Royal Bank Of Canada decreased their target price on Biohaven from $19.00 to $9.00 and set a “sector perform” rating for the company in a research report on Thursday, November 6th. BTIG Research reissued a “buy” rating and set a $16.00 price objective on shares of Biohaven in a research note on Tuesday, November 18th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $11.00 target price on shares of Biohaven in a research note on Friday, December 26th.

Biohaven Stock Performance

Shares of NYSE:BHVN opened at $11.85 on Friday. The stock has a market capitalization of $1.25 billion, a P/E ratio of -1.56 and a beta of 1.14. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 1.91. Biohaven has a 1-year low of $7.48 and a 1-year high of $44.28. The business has a 50-day moving average price of $11.05 and a two-hundred day moving average price of $13.13.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.91) by $0.27. Equities analysts predict that Biohaven will post -8.9 earnings per share for the current year.

Insiders Place Their Bets

In other Biohaven news, CAO George C. Clark bought 17,000 shares of Biohaven stock in a transaction on Monday, November 17th. The shares were purchased at an average cost of $8.52 per share, for a total transaction of $144,840.00. Following the completion of the acquisition, the chief accounting officer owned 20,000 shares in the company, valued at approximately $170,400. The trade was a 566.67% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John W. Childs purchased 3,333,333 shares of the stock in a transaction on Thursday, November 13th. The stock was acquired at an average price of $7.50 per share, with a total value of $24,999,997.50. Following the completion of the acquisition, the director directly owned 5,653,904 shares of the company’s stock, valued at approximately $42,404,280. This represents a 143.64% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 4,416,999 shares of company stock worth $33,144,833. 16.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Biohaven

Several large investors have recently made changes to their positions in BHVN. Emerald Mutual Fund Advisers Trust lifted its position in Biohaven by 0.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 173,656 shares of the company’s stock valued at $2,607,000 after acquiring an additional 657 shares in the last quarter. Sigma Planning Corp lifted its holdings in shares of Biohaven by 9.2% in the fourth quarter. Sigma Planning Corp now owns 13,613 shares of the company’s stock valued at $154,000 after purchasing an additional 1,146 shares in the last quarter. Elkhorn Partners Limited Partnership grew its holdings in shares of Biohaven by 26.1% during the second quarter. Elkhorn Partners Limited Partnership now owns 5,800 shares of the company’s stock worth $82,000 after buying an additional 1,200 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after acquiring an additional 1,268 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its stake in shares of Biohaven by 5.8% during the 2nd quarter. Advisors Asset Management Inc. now owns 25,288 shares of the company’s stock worth $357,000 after acquiring an additional 1,383 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.